14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan . Full study 👉🏼https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901782-4/fulltext
@TheLancet #ESMO26
34 views · 0 likes · 0 reposts · 0 replies
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase
https://esmocongress.esmo.orgLong-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.orgOutcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study
https://esmocongress.esmo.orgBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial
https://esmocongress.esmo.orgFinal overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic
https://esmocongress.esmo.orgSource: Vania Wisdom · x.com